Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.22.1
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Nov. 30, 2019
Jan. 31, 2018
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Revenue recognized         $ 5,467,000 $ 4,827,000    
Deferred revenue         7,773,000   $ 10,181,000  
Global Blood Therapeutics                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue         6,926,000   8,913,000  
Global Blood Therapeutics | Collaboration Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Initial period of research term 3 years              
Additional extension period for research term upon mutual agreement 1 year              
Upfront payment receivable $ 20,000,000.0              
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000.0              
Agreement termination, prior written notice if notice delivered during the research term 9 months              
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days              
Total transaction price $ 60,000,000.0       54,200,000   54,200,000 $ 60,000,000.0
Upfront non-refundable and non-creditable payment 20,000,000.0              
Reimbursable costs $ 40,000,000.0              
Change in total transaction price         0      
Revenue recognized         5,100,000 4,000,000.0    
Deferred revenue         6,900,000      
Global Blood Therapeutics | Collaboration Agreement | Maximum                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Period of extension of initial research term 2 years              
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000.0              
Incyte                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Revenue recognized         400,000 800,000    
Deferred revenue         847,000 $ 800,000 $ 1,268,000  
Incyte | Stock Purchase Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Aggregate purchase price       $ 10,000,000.0        
Shares issued       793,021        
Share price (in dollars per share)       $ 12.61        
Premium to volume-weighted sale price of shares (as a percent)       30.00%        
Trading days within which the purchase price represents a thirty percent (30%) premium to the volume-weighted sale price of the shares       15 days        
Incyte | Collaboration Agreement                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total transaction price   $ 12,300,000 $ 12,800,000   12,800,000      
Upfront non-refundable and non-creditable payment         2,500,000      
Up-front consideration       $ 10,000,000.0        
Up-front consideration, cash       2,500,000        
Up-front consideration, pre-paid research funding       $ 7,500,000        
Prepaid research amount         7,500,000      
Premium paid on equity investment         2,300,000      
Collaboration agreement additional consideration incurred         $ 500,000